Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06458127
Other study ID # 24-077
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date March 31, 2026

Study information

Verified date June 2024
Source Massachusetts General Hospital
Contact Areej El-Jawahri, MD
Phone 617-724-4000
Email ael-jawahri@mgb.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is evaluating the feasibility and acceptability of implementing a telehealth palliative care intervention in patients with moderate to severe chronic graft-versus-host disease.


Description:

Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity among survivors of allogeneic hematopoietic cell transplantation (HCT) patients. Allogeneic HCT is a potentially curative procedure for a variety of hematologic malignancies and involves infusion of donor cells to establish marrow and immune function. Recent advances in risk determination, treatment (i.e., improved safety, use of a variety of donors), prevention of complications, and reduced-toxicity regimens have expanded the eligible patient population, and increased survival of patients who undergo HCT. However, development of cGVHD is a leading complication of allogenic HCT and impacts over 50% of survivors. It develops 3-18 months post-allogeneic HCT and is a main cause of post-HCT morbidity and mortality. cGVHD is a debilitating immunologic syndrome which attacks different organs in the body, resulting in a wide range of disruptive and unpredictable symptoms. Additionally, side effects of cGVHD include psychological distress with many patients reporting clinical levels of depression and anxiety. Further, patients with cGVHD are also at high risk for late effects, such as skeletal complications, secondary cancers, cardiovascular disease, and thromboembolic events. As a result of this diverse symptom burden, the side effects and psychological distress from illness, and uncertainty of the illness course, patients living with cGVHD experience diminished QOL. Patients with cGVHD struggle to manage their chronic condition, exacerbated with treatment related side effects of physical symptoms, functional limitations, psychological distress, and impaired QOL. Specialty palliative care clinicians have expertise in complex symptom management, facilitate coping with illness and improvement of QOL in cancer patients. Telehealth in various forms has been long studied as an approach to increase access to care, and a care model for management of chronic diseases. Expanding on our prior experience with the specialty palliative care model for HCT patients, we aim to develop a telehealth specialty PC model for patients with moderate to severe cGVHD. In this single-arm pilot study, we will test the feasibility and acceptability of a once a month tele-palliative care appointment over the course of 3 months to address the symptom burden, psychological distress and disease uncertainty of cGVHD patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date March 31, 2026
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1) Adult patients (>18 years) - 2) Have moderate to severe cGVHD based on their oncology clinician assessment as documented in the electronic health record. - 3) Ability to comprehend and speak English, and to read and respond to questions in English Please note that this is a proof-of-concept study, and we only include patients who comprehend, read, and respond to questions in English since the study instruments are all available in English. However, as we have done in prior studies, we will expand the population in a future efficacy trial. Exclusion Criteria: - 1) Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures - 2) Patients who have already consulted or are currently consulting palliative care

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tele-palliative care visit
Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.

Locations

Country Name City State
United States Massachusetts General Hospital (MGH) Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of the tele-palliative care intervention To calculate two measures of feasibility: 1) the proportion of eligible patients who are approached and agree to participate, with 95% confidence interval, and 2) the proportion of enrolled participants who complete at least two of the three intervention visits, with 95% confidence interval.
The intervention will be deemed feasible if at least 60% of patients with moderate to severe cGVHD agree to participate in the study.
The intervention will be deemed feasible if at least 70% of participants attend at least two of the three intervention visits.
Week 12
Secondary Acceptability of the tele-palliative care intervention To calculate two acceptability measures: 1) the proportion of participants who score >20 on the Client Satisfaction Questionnaire (CSQ-8) with 95% confidence interval, and 2) the proportion of participants who complete the baseline and 3-month patient surveys with 95% confidence interval.
Total scores of CSQ-8 range from 8 to 32, with the higher score indicating greater satisfaction.
The proposed intervention will be deemed acceptable if at least 60% of participants score >20 on the CSQ-8.
Week 12
See also
  Status Clinical Trial Phase
Completed NCT02991846 - A Prospective Observational Study for Evaluating CGVHD
Recruiting NCT02291770 - Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Phase 3
Terminated NCT01226420 - Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Phase 2
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus Phase 2
Completed NCT02411474 - Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD N/A
Completed NCT02040623 - Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) Phase 2
Active, not recruiting NCT01158105 - Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) Phase 2
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Active, not recruiting NCT01366092 - Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 2
Recruiting NCT05690971 - Psychosocial Mobile App for Chronic Graft-Versus-Host Disease N/A
Recruiting NCT02918188 - Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD Phase 2
Recruiting NCT01765660 - Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease Phase 2
Completed NCT01956903 - Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. Phase 1/Phase 2
Terminated NCT03584516 - GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Phase 2/Phase 3
Recruiting NCT04692376 - MSC for Treatment of cGVHD After Allo-HSCT Phase 2
Completed NCT02966301 - Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Phase 2
Terminated NCT01898377 - Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2